The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Identifying high-risk multiple myeloma patient subgroups using genetic and clinical factors
Eileen Boyle, MD, PhD, NYU Langone, New York City, NY, outlines the clinical and genetic factors contributing to poorer outcomes and response to treatment in multiple myeloma, and discusses how the identification of high-risk subgroups might help to appropriately treat those patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
